An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE)
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Brazikumab (Primary) ; Brazikumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms Intrepid; INTREPID OLE
- Sponsors AbbVie; Allergan; AstraZeneca; AstraZeneca AB
Most Recent Events
- 24 Nov 2023 The trial has been completed in Germany (End Date: 19 Sep 2023), according to European Clinical Trials Database record.
- 19 Oct 2023 Status changed from active, no longer recruiting to discontinued.
- 06 Sep 2023 This trial has been discontinued in Spain (Global end date: 1 June 2023).